Objectives: We aimed to determine the frequency of PTEN (phosphatase with tensin homology deleted in chromosome 10) hypermethylation in renal cell carcinoma (RCC) and its impact on overall (OS) and disease-free survival (DFS). The association between PTEN hypermethylation and clinic and pathologic factors was also analyzed. Materials and Methods: The authors analyzed 137 patients who had undergone a radical or partial nephrectomy between 1997 and 2011. The methylation pattern was quantified individually at multiple CpG islands that are located on the exon 1 of PTEN gene by pyrosequencing. Results: Mean follow-up was 32 . 3 months. PTEN hypermethylation was detected with a low frequency (3.6%). There were no deaths or disease recurrence among patients with PTEN hypermethylation. Determining the association between PTEN hypermethylation and clinical and pathological factors was not possible due to the low frequency observed. Conclusion: The results show that the methylation of promoter CpG sites in PTEN is relatively infrequent in renal carcinogenesis and has no prognostic impact on survival.
Hyung, L.K., Seligson, D., Liu, X., et al. (2005) Tumors Using Markers to Predict the Survival of Metastatic Renal Cell Patients with Carcinoma. Journal of Urology, 173, 1496-1501. https://doi.org/10.1097/01.ju.0000154351.37249.f0
Lam, J.S., Shvarts, O., Leppert, J.T., Figline, R.A. and Belldegrun, A.S. (2005) Renal Cell Carcinoma 2005: New Frontiers in Staging, Prognostication and Targeted Molecular Therapy. Journal of Urology, 173, 1853-1862. https://doi.org/10.1097/01.ju.0000165693.68449.c3
Sansal, I. and Sellers, W.R. (2004) The Biology and Clinical Relevance of the PTEN Tumor Supressor Pathway. Journal of Clinical Oncology, 22, 2954-2963. https://doi.org/10.1200/JCO.2004.02.141
Sakurada, A., Suzuki, A., Sato, M., et al. (1997) Infrequent Genetic Alterations of the PTEN/MMAC1 Gene in Japanese Patients with Primary Cancers of the Breast, Lung, Pancreas, Kidney, and Ovary. Japanese Journal of Cancer Research, 88, 1025-1028. https://doi.org/10.1111/j.1349-7006.1997.tb00324.x
Kisseljova, N.P. and Kisseljov, F.L. (2005) DNA Demethylation and Carcinogenesis. Biochemistry, 70, 743-752. https://doi.org/10.1007/s10541-005-0179-z
Kondo, K., Yao, M., Kobayashi, K., et al. (2001) PTEN/MMAC1/TEP1 Mutations in Human Primary Renal Cell Carcinomas and Renal Carcinoma Cell Lines. International Journal of Cancer, 91, 219-224. https://doi.org/10.1002/1097-0215(200002)9999:9999 3.0.CO;2-S
Sükosd, F., Digon, B., Fischer, J., Pietsch, T. and Kovacs, G. (2001) Allelic Loss at 10q23.3 But Lack of Mutation of PTEN/MMAC1 in Renal Cell Carcinoma Chromophobia. Cancer Genetics and Cytogenetics, 128, 161-163. https://doi.org/10.1016/S0165-4608(01)00413-7
Teng, D.H., Hu, R., Lin, H., et al. (1997) MMAC1/PTEN Mutations in Primary Tumor Specimens and Tumor Cell Lines. Cancer Research, 57, 5221-5225.
Hara, S., Oya, M., Mizuno, R., Horiguchi, A., Marumo, K. and Murai, M. (2005) Akt Activation in Renal Cell Carcinoma: Contribution of a Decreased PTEN Expression and the Induction of Apoptosis by an Akt Inhibitor. Annals of Oncology, 16, 928-933. https://doi.org/10.1093/annonc/mdi182
Lee, J.S., Kim, H.S., Kim, Y.B., Lee, M.C. and Park, C.S. (2003) Expression of PTEN in Renal Cell Carcinoma and Its Relation to Tumor Behavior and Growth. Journal of Surgical Oncology, 84, 166-172. https://doi.org/10.1002/jso.10302
Figlin, R.A., de Souza, P., McDermott, D., et al. (2009) Analysis of PTEN and Hif-1alpha and the Correlation with Efficacy in Patients with Advanced Renal Cell Carcinoma Treated with Tensirolimus versus Interpheron-Alpha. Cancer, 115, 3651-3660. https://doi.org/10.1002/cncr.24438
Fuhrman, S.A., Lasky, L.C. and Limas, C. (1982) Prognostic Significance of Morphologic Parameters in Renal Cell Carcinoma. The American Journal of Surgical Pathology, 6, 655-663. https://doi.org/10.1097/00000478-198210000-00007
Bruder, E., Passera, O., Harms, D., et al. (2004) Morphologic and Molecular Characterization of Renal Cell Carcinoma in Children and Young Adults. The American Journal of Surgical Pathology, 28, 1117-1132. https://doi.org/10.1097/01.pas.0000131558.32412.40
Sobin, L.H. and Wittekind, C. (2004) TNM Classification of Malignant Tumours. 6th Edition, INCA, Rio de Janeiro. https://doi.org/10.1002/0471463752
Ehrich, M., Zoll, S., Sur, S. and van den Boom, D. (2007) A New Method for Accurate Assessment of DNA Quality after Bisulfite Treatment. Nucleic Acids Research, 35, 1-8. https://doi.org/10.1093/nar/gkl1134
Sato, K., Tamura, G., Tsuchiya, T., et al. (2002) Analysis of Genetic and Epigenetic Alterations of the PTEN Gene in Gastric Cancer. Virchows Archiv, 440, 160-165. https://doi.org/10.1007/s004280100499
Kishi, M., Nakamura, M., Nishimine, M., Ikuta, M., Kirita, T. and Konishi, N. (2004) Genetic and Epigenetic Alteration Profiles for Multiple Genes in Salivary Gland Carcinomas. Oral Oncology, 41, 161-169. https://doi.org/10.1016/j.oraloncology.2004.08.004
Baeza, N., Weller, M., Yonekawa, Y., Kleihues, P. and Ohgaki, H. (2003) PTEN Methylation and Expression in Glioblastomas. Acta Neuropathologica, 106, 479-485. https://doi.org/10.1007/s00401-003-0748-4
Cheung, T.H., Lo, K.W., Yim, S.F., et al. (2004) Epigenetic and Genetic Alternation of PTEN in Cervical Neoplasm. Gynecologic Oncology, 93, 621-627. https://doi.org/10.1016/j.ygyno.2004.03.013
Mirmohammadsadegh, A., Marini, A., Nambiar, S., et al. (2006) Epigenetic Silencing of the PTEN Gene in Melanoma. Cancer Research, 66, 6546-6552. https://doi.org/10.1158/0008-5472.CAN-06-0384
Tam, K.F., Liu, V.W., Liu, S.S., et al. (2007) Methylation Profile in Benign, Borderline and Malignant Ovarian Tumors. Journal of Cancer Research and Clinical Oncology, 133, 331-341. https://doi.org/10.1007/s00432-006-0178-5
Muggerud, A.A., Ronneberg, J.A., Warnberg, F., et al. (2010) Frequent Aberrant DNA Methylation of ABCB1, FOXC1, PTEN and PPP2R2B in Ductal Carcinoma in Situ and Early Invasive Breast Cancer. Breast Cancer Research, 12, R3. https://doi.org/10.1186/bcr2466
Yim, E.K., Peng, G., Dai, H., et al. (2009) Rak Functions as a Tumor Suppressor by Regulating PTEN Protein Stability and Functions. Cancer Cell, 15, 304-314. https://doi.org/10.1016/j.ccr.2009.02.012
Kim, D.S., Lee, S.M., Yoon, G.S., Choi, J.E. and Park, J.Y. (2010) Infrequent Hypermethylation of the PTEN Gene in Korean Non-Small-Cell Lung Cancers. Cancer Science, 101, 568-572. https://doi.org/10.1111/j.1349-7006.2009.01406.x
Shames, D.S., Minna, J.D. and Gazdar, S.F. (2007) Methods for Detecting DNA Methylation in Tumors: From Bench to Bedside. Cancer Letters, 251, 187-198. https://doi.org/10.1016/j.canlet.2006.10.014
Zysman, M.A., Chapman, W. and Bapat, B. (2002) Considerations When Analyzing the Methylation Status of PTEN Tumor Suppressor Gene. The American Journal of Pathology, 160, 795-800. https://doi.org/10.1016/S0002-9440(10)64902-4
Morita, R., Saito, S., Ishikawa, J., et al. (1991) Common Regions of Deletion on Chromosomes 5q, 6q, and 10q in Renal Cell Carcinoma. Cancer Research, 51, 5817-5820.
Velickovic, M., Delahunt, B., McIver, B. and Grebe, S.K. (2002) Intragenic PTEN/MMAC1 Loss of Heterozygosity in Conventional (Clear-Cell) Renal Cell Carcinoma is Associated with Poor Patient Prognosis. Modern Pathology, 15, 479-485. https://doi.org/10.1038/modpathol.3880551
Zaman, M.S., Thamminana, S., Shahryari, V., et al. (2012) Inhibition of PTEN Gene Expression by Oncogenic miR-23b-3p in Renal Cancer. PLoS ONE, 7, e50203. https://doi.org/10.1371/journal.pone.0050203